We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+6.18%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$17.6B
AUM Growth
+$224M
Cap. Flow
-$30.2M
Cap. Flow %
-0.17%
Top 10 Hldgs %
87.48%
Holding
123
New
5
Increased
24
Reduced
7
Closed
6

Top Buys

Rank Stock Value
1
REPL icon
Replimune Group
REPL
+$32.5M
2
ASND icon
Ascendis Pharma A/S
ASND
+$29.3M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$23.6M
4
CCXI
ChemoCentryx, Inc.
CCXI
+$19.3M
5
NRIX icon
Nurix Therapeutics
NRIX
+$16.2M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$63.5M
2
LEGN icon
Legend Biotech
LEGN
+$48.7M
3
AXSM icon
Axsome Therapeutics
AXSM
+$25.3M
4
MRUS
Merus
MRUS
+$21.8M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$9.64M

Sector Composition

Rank Sector Weight
1 Healthcare 99.55%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RYTM icon
51
Rhythm Pharmaceuticals
RYTM
$7.57B
$17.1M 0.1%
4,125,062
– –
OPT
52
DELISTED
Opthea Limited American Depositary Shares
OPT
$17M 0.1%
2,696,191
– –
ADAP
53
DELISTED
Adaptimmune Therapeutics
ADAP
$16.7M 0.09%
9,830,877
– –
CRNX icon
54
Crinetics Pharmaceuticals
CRNX
$8.99B
$15.4M 0.09%
827,480
– –
TCDA
55
DELISTED
Tricida, Inc. Common Stock
TCDA
$14.6M 0.08%
1,503,090
-228,624
-13% -$2.18M
FMTX
56
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
$14M 0.08%
2,024,876
– –
FLGT icon
57
Fulgent Genetics
FLGT
$548M
$11M 0.06%
201,444
– –
BLUE
58
DELISTED
bluebird bio
BLUE
$10.3M 0.06%
124,986
– –
RLMD icon
59
Relmada Therapeutics
RLMD
$494M
$9.4M 0.05%
495,113
– –
DICE
60
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$9.13M 0.05%
588,235
– –
ZYME icon
61
Zymeworks
ZYME
$2.05B
$9.05M 0.05%
1,708,472
– –
KRTX
62
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$8.85M 0.05%
69,966
– –
TCRX icon
63
TScan Therapeutics
TCRX
$52.8M
$8.76M 0.05%
2,784,792
+1,359,792
+95% +$3.72M
ANAB icon
64
AnaptysBio
ANAB
$1.71B
$8.67M 0.05%
427,179
– –
KYNB
65
Kyntra Bio
KYNB
$30.4M
$8.61M 0.05%
32,629
+9,359
+40% +$2.39M
CYT
66
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
$7.9M 0.04%
2,643,640
+1,831,000
+225% +$4.68M
SRZN icon
67
Surrozen
SRZN
$282M
$7.5M 0.04%
166,667
– –
RETA
68
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$6.81M 0.04%
223,976
– –
ACHL
69
DELISTED
Achilles Therapeutics
ACHL
$6.53M 0.04%
2,591,366
– –
CBAY
70
DELISTED
Cymabay Therapeutics
CBAY
$6.4M 0.04%
2,170,464
– –
BCEL
71
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$6.32M 0.04%
3,532,760
– –
TLIS
72
DELISTED
Talis Biomedical Corporation Common Stock
TLIS
$6.19M 0.04%
508,322
– –
HRMY icon
73
Harmony Biosciences
HRMY
$2.22B
$6.03M 0.03%
123,600
– –
ATRA icon
74
Atara Biotherapeutics
ATRA
$97.4M
$5.8M 0.03%
+29,767
New +$4.86M
VOR icon
75
Vor Biopharma
VOR
$1.38B
$5.66M 0.03%
+56,938
New +$5.83M
1 2
3
4 5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q2 2022 Portfolio in Review

As of Q2 2022, Julian Baker held 123 positions worth $17.6B, up 1.3% from $17.4B the previous quarter. Its ten largest holdings account for 87% of the portfolio.

Julian Baker's Q2 2022 filing shows 5 new, 24 increased, 7 reduced and 6 closed positions. Its largest new stake was Vor Biopharma: 56,938 shares worth $5.66M. The largest sale was Neurocrine Biosciences, an estimated $63.5M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.

  • Julian Baker's largest Q2 2022 buy was Vor Biopharma: 56,938 shares worth $5.66M.
  • Julian Baker added most to Replimune Group in Q2 2022, an estimated $32.5M increase.
  • Julian Baker's biggest Q2 2022 reduction was Legend Biotech, cutting an estimated $48.7M.
  • Julian Baker fully exited Neurocrine Biosciences in Q2 2022, selling an estimated $63.5M.
  • Julian Baker's ten largest holdings make up 87% of its $17.6B portfolio in Q2 2022.
  • Julian Baker opened 5 new positions and closed 6 in Q2 2022.
  • Julian Baker's portfolio value rose 1.3% quarter-over-quarter to $17.6B.

Based on Baker Bros. Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.